Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

Radiotherapy 3entinostat 2Trastuzumab 2Nivolumab 2Ipilimumab 2CTLA-4 Antigen 2tipifarnib 1oncogene protein E7, Human papillomavirus type 16 1fludarabine phosphate 1fludarabine 1bintrafusp alfa protein, human 1aldesleukin 1Watchful Waiting 1Therapeutics 1Specimen Handling 1Ritonavir 1Respiratory Function Tests 1Radiation 1Psychiatric Rehabilitation 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1Observation 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Loperamide 1Interleukin-2 1Interleukin-12 Subunit p35 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Vulvar Neoplasms × Diphenoxylate × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡